AgomAb Therapeutics NV

AgomAb Therapeutics NV financial statements

AgomAb Therapeutics NV's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

FY2025

RevenueEUR 0EODHD
Net income−EUR 62.55MEODHD
Cash and equivalentsEUR 86.42MEODHD
Total debtEUR 1.25MEODHD

AgomAb Therapeutics NV financials on 6ix · AgomAb Therapeutics NV on 6ix